At Juno, our goal is twofold: increase patient access to high quality, lifesaving medicines and increase value within the Australian healthcare system.
Biosimilars and interchangeable biologic products present an opportunity to patients, healthcare professionals and the government, by providing increased patient access to therapies, whilst helping maintain the long-term viability and financial sustainability of the Australian and New Zealand healthcare systems.
We believe that we have the right expertise and strategies to effectively partner with biologic developers whose brands are reaching their patent expiry, plus biosimilar developers with plans to launch in Australia and New Zealand.
Biosimilars are a sub-category of biologic medicines5. They are follow-on or alternative versions of existing, originator or reference biologic medicines whose marketing exclusivity rights have expired5.
To be granted approval as a biosimilar by regulatory authorities, the product must undergo rigorous comparability analyses to prove it possesses similar quality, efficacy and safety to the reference biological medicine with which it has been compared5.
